Collet, L.; Péron, J.; Penault-Llorca, F.; Pujol, P.; Lopez, J.; Freyer, G.; You, B.
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers 2022, 14, 599.
https://doi.org/10.3390/cancers14030599
AMA Style
Collet L, Péron J, Penault-Llorca F, Pujol P, Lopez J, Freyer G, You B.
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers. 2022; 14(3):599.
https://doi.org/10.3390/cancers14030599
Chicago/Turabian Style
Collet, Laetitia, Julien Péron, Frédérique Penault-Llorca, Pascal Pujol, Jonathan Lopez, Gilles Freyer, and Benoît You.
2022. "PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers" Cancers 14, no. 3: 599.
https://doi.org/10.3390/cancers14030599
APA Style
Collet, L., Péron, J., Penault-Llorca, F., Pujol, P., Lopez, J., Freyer, G., & You, B.
(2022). PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers, 14(3), 599.
https://doi.org/10.3390/cancers14030599